The benefits of non-viral, scalable transfection for assay development, protein production and cell therapy enablement
Date: Tuesday Sept 24, 2024
Time: 10:00-11:00 AM
In-person
NIH
Building 10 FAES Classrooms
Room 7
Bethesda, MD
About the workshop
Engineering cells to develop biological assays, produce recombinant proteins or create cellular therapies requires highly efficient, scalable and reproducible methods for transfecting nucleic acids, proteins and other macromolecules. However, cell line development is a lengthy process that becomes even more challenging when working with complex assays, difficult to express products, or expensive and time-consuming viral methods. Moreover, stable cell lines are rarely suitable for cell and gene therapy applications. In this presentation, we’ll discuss the benefits of transient transfection at overcoming the limitations of engineered, stable cell lines and viral-based workflows. In particular, we’ll focus on the advantages of scalable electroporation for efficiently engineering primary cells, stem cells and other cell types for all phases of therapeutic development, from basic research to cGMP manufacturing. Data will be shared on CRISPR-based gene editing, assay development for membrane protein screening, and rapid production of antibodies in CHO cells.
RSVP
Fill out the form below to attend the in-person seminar